Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.

Literature DB >> 29610752

First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.

Byeong-Ho Jeong¹, Sang-Won Um¹.

Abstract

Entities: Chemical Disease Gene Species

Year: 2018 PMID： 29610752 PMCID： PMC5879504 DOI： 10.21037/atm.2017.12.30

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

22 in total

1. Intratumoral heterogeneity and biomarkers for transformation into small cell lung carcinomas from lung adenocarcinomas.

Authors: Hyun Lee; Sang-Won Um
Journal: J Thorac Dis Date: 2017-11 Impact factor: 2.895

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors: Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal: N Engl J Med Date: 2010-06-24 Impact factor: 91.245

3. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors: Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal: Lancet Oncol Date: 2012-03-26 Impact factor: 41.316

4. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.

Authors: Tao Jiang; Caicun Zhou
Journal: Transl Lung Cancer Res Date: 2014-12

5. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Authors: Federico Cappuzzo; Alessandro Morabito; Nicola Normanno; Paolo Bidoli; Alessandro Del Conte; Laura Giannetta; Agnese Montanino; Francesca Mazzoni; Roberta Buosi; Marco Angelo Burgio; Giulio Cerea; Rita Chiari; Diego Cortinovis; Giovanna Finocchiaro; Luisa Foltran; Maria Rita Migliorino; Marcello Tiseo; Silvia Ferrari; Filippo De Marinis
Journal: Lung Cancer Date: 2016-06-14 Impact factor: 5.705

6. Screening for epidermal growth factor receptor mutations in lung cancer.

Authors: Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245

7. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Authors: Kenneth S Thress; Cloud P Paweletz; Enriqueta Felip; Byoung Chul Cho; Daniel Stetson; Brian Dougherty; Zhongwu Lai; Aleksandra Markovets; Ana Vivancos; Yanan Kuang; Dalia Ercan; Sarah E Matthews; Mireille Cantarini; J Carl Barrett; Pasi A Jänne; Geoffrey R Oxnard
Journal: Nat Med Date: 2015-05-04 Impact factor: 53.440

8. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors: Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal: N Engl J Med Date: 2016-12-06 Impact factor: 91.245

First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.

1. Intratumoral heterogeneity and biomarkers for transformation into small cell lung carcinomas from lung adenocarcinomas.

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

3. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

4. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.

5. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

6. Screening for epidermal growth factor receptor mutations in lung cancer.

7. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

8. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

9. Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

10. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

1. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use.

2. Risk Factors for Thyroid Dysfunction in Patients with Advanced Non-Small-Cell Lung Cancer Treated with PD-1 Antibody.